FindTrial
Sign In

A multicenter study of levosimendan in improving weaning success of VA-ECMO

A multicenter study of levosimendan in improving weaning success of VA-ECMO

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068067
Enrollment
Unknown
Registered
2023-02-06
Start date
2023-02-28
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiogenic shock

Interventions

Case group (Levosimendan was applied before ECMO was withdrawn):None
control group (Levosimendan should not be used for routine treatment):None

Sponsors

Zhengzhou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients older than 18 years of age who underwent VA-ECMO for cardiogenic shock and finally reached the weaning criteria.

Exclusion criteria

Exclusion criteria: Patients who received VA-ECMO assistance for less than 48 hours and could not be weaved due to irreversible disease and were assisted with intra-aortic balloon pump (IABP) had severe hepatic and renal insufficiency, uncontrolled thyroid disease, severe primary valvular disease, and pericardial disease.

Design outcomes

Primary

MeasureTime frame
Weaning success rate;—

Secondary

MeasureTime frame
28-day mortality rate;—

Countries

China

Contacts

Public ContactHong-Yu Wang

Zhengzhou People's Hospital

hongyu260@163.com+86 13674950311

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026